← All trials
NCT04535063
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 18, 2020
- Primary completion
- Dec 30, 2020
- Completion date
- Feb 25, 2021
- First posted
- Sep 1, 2020
- Last posted
- Sep 2, 2020
- Enrollment
- 200
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Centro de Educación Medica e Investigaciones Clínicas Norberto QuirnoLead sponsor
- Centro de Educación Medica e Investigaciones Clínicas Norberto QuirnoReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.